Cerebral venous sinus thrombosis risk across various oral contraceptives: a disproportionality analysis of the FDA adverse event reporting system.

HOME
>
論文・技術情報
>
Cerebral venous sinus thrombosis risk across various oral contraceptives: a disproportionality analysis of the FDA adverse event reporting system.

アブストラクト	OBJECTIVE: Estrogen-containing oral contraceptives (OCPs) increase the risk of thromboembolic events including cerebral venous sinus thromboses (CVSTs). However, robust pharmacovigilance data comparing CVST risk across OCPs remain limited. STUDY DESIGN: The FDA Adverse Event Reporting System (FAERS) was used to investigate which OCPs are associated with a disproportionally high CVST reporting. RESULTS: There were 479 reports of CVST across OCPs. Estrogen containing contraceptives were associated with disproportionally high CVST reporting, with ethinyl estradiol + drosperinone exhibiting the most substantial association (reporting odds ratio: 38.1, 345 cases). CONCLUSION: Clinicians should educate those taking estrogen-containing OCPs on how to identify CVST symptoms.
ジャーナル名	Journal of neurology
Pubmed追加日	2026/5/16
投稿者	Balshi, Alexandra
組織名	Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.;alexandra_balshi@hms.harvard.edu.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/42141300/